TRCT
UBX

Tower Research Capital (TRC)’s Unity Biotechnology UBX Stock Holding History

Tower Research Capital (TRC)’s Portfolio UBX Stock Details UBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,395
Closed -$920 – 5647
2025
Q2 		$920 Buy
2,395
+377
+19% +$323 ﹤0.01% 4911
2025
Q1 		$2.34K Sell
2,018
-636
-24% -$1.15K ﹤0.01% 4562
2024
Q4 		$2.59K Buy
2,654
+595
+29% +$739 ﹤0.01% 4811
2024
Q3 		$3.03K Sell
2,059
-2,740
-57% -$4.02K ﹤0.01% 4904
2024
Q2 		$6.48K Sell
4,799
-113
-2% -$172 ﹤0.01% 4574
2024
Q1 		$8.05K Buy
4,912
+2,484
+102% +$4.31K ﹤0.01% 4089
2023
Q4 		$4.69K Buy
+2,428
New +$4.51K ﹤0.01% 4928
2023
Q1 		– Sell
-10,349
Closed -$28K – 6290
2022
Q4 		$28K Buy
10,349
+10,345
+258,625% +$30.1K ﹤0.01% 2820
2022
Q3 		$0 Sell
4
-1,690
-100% -$10.7K ﹤0.01% 6507
2022
Q2 		$10K Buy
1,694
+1,560
+1,164% +$13K ﹤0.01% 4489
2022
Q1 		$2K Sell
134
-569
-81% -$6.38K ﹤0.01% 5607
2021
Q4 		$10K Sell
703
-924
-57% -$20.2K ﹤0.01% 4612
2021
Q3 		$48K Buy
1,627
+1,212
+292% +$42.8K ﹤0.01% 3003
2021
Q2 		$19K Buy
415
+29
+8% +$1.4K ﹤0.01% 3952
2021
Q1 		$23K Sell
386
-150
-28% -$10.2K ﹤0.01% 3784
2020
Q4 		$28K Sell
536
-2,984
-85% -$144K ﹤0.01% 3631
2020
Q3 		$121K Buy
3,520
+2,941
+508% +$186K ﹤0.01% 3000
2020
Q2 		$51K Buy
579
+459
+383% +$34K ﹤0.01% 3034
2020
Q1 		$7K Sell
120
-507
-81% -$32K ﹤0.01% 2195
2019
Q4 		$45K Sell
627
-114
-15% -$8.04K ﹤0.01% 1415
2019
Q3 		$45K Buy
+741
New +$52.4K ﹤0.01% 1872
2019
Q2 		– Sell
-655
Closed -$53K – 4313
2019
Q1 		$53K Buy
+655
New +$74.3K ﹤0.01% 1744
2018
Q4 		– Sell
-99
Closed -$16K – 4367
2018
Q3 		$16K Buy
+99
New +$16.3K ﹤0.01% 2491

Other funds holding UBX

Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
AIP
Ameritas Investment Partners Lincoln, Nebraska $3.25B AUM 28.52% 1-Year Est. Return
AWM
AllSquare Wealth Management Albany, New York $189M AUM 14.89% 1-Year Est. Return

Tower Research Capital (TRC)'s UBX Position: Q3 2025 in Review

Tower Research Capital (TRC) sold out of Unity Biotechnology (UBX) in Q3 2025, closing a stake of 2,395 shares — an estimated $920 sold.

Tower Research Capital (TRC) first reported a position in UBX in Q3 2018 and held it in 23 quarters. The position peaked at $121K in Q3 2020. 6 funds tracked by Wall St. Rank hold UBX as of Q3 2025.

  • Tower Research Capital (TRC) reported no remaining Unity Biotechnology position as of Q3 2025 after selling out during the quarter.
  • Tower Research Capital (TRC) sold 2,395 Unity Biotechnology shares in Q3 2025, an estimated $920.
  • Tower Research Capital (TRC) first reported a position in Unity Biotechnology in Q3 2018 and held it in 23 quarters.
  • Tower Research Capital (TRC)'s Unity Biotechnology position peaked at $121K in Q3 2020.
  • 6 funds tracked by Wall St. Rank held Unity Biotechnology as of Q3 2025.

Based on Tower Research Capital (TRC)'s 13F filing for Q3 2025, filed 14 Nov 2025.